Limosilactobacillus reuteri R0830
Also known as: Limosilactobacillus reuteri R0830, Lactobacillus reuteri R0830
Overview
Limosilactobacillus reuteri R0830 is a specific strain of lactic acid bacteria, a type of probiotic naturally found in the human gastrointestinal tract. As a probiotic supplement, it is primarily used to support gut health, modulate the gut microbiota, and alleviate various gastrointestinal disorders. While L. reuteri strains in general are well-researched for their ability to colonize the gut, produce antimicrobial substances like reuterin, and modulate immune responses, specific high-quality clinical evidence directly on the R0830 strain is limited. Most of the robust research, including randomized controlled trials and meta-analyses, focuses on other well-studied L. reuteri strains such as DSM 17938 and ATCC PTA 6475. Therefore, the benefits and mechanisms attributed to R0830 are largely extrapolated from the broader L. reuteri species and its more extensively studied strains.
Benefits
While direct, high-quality clinical evidence specifically for Limosilactobacillus reuteri R0830 is limited, benefits are largely extrapolated from extensive research on closely related L. reuteri strains. These strains have demonstrated efficacy in several areas. They are most notably effective in reducing symptoms of infantile colic, with meta-analyses showing significant reductions in crying duration and frequency (p < 0.05). For acute diarrhea in children, L. reuteri strains have been shown to reduce diarrhea duration and improve gut symptoms significantly (p < 0.05). In adults with Irritable Bowel Syndrome (IBS), certain L. reuteri strains have improved abdominal pain, bloating, and stool consistency compared to placebo (p < 0.05). These benefits are supported by randomized controlled trials and meta-analyses, indicating moderate to strong evidence for the species. Some strains may also offer secondary benefits like immune modulation and reduced gut inflammation, though this is highly strain-dependent and less robustly evidenced for R0830 specifically. Benefits typically emerge within 1 to 4 weeks of consistent supplementation.
How it works
Limosilactobacillus reuteri R0830, like other L. reuteri strains, primarily acts within the gastrointestinal tract. Its mechanism involves the production of antimicrobial substances, notably reuterin, which helps inhibit the growth of pathogenic bacteria. It also modulates the composition of the gut microbiota, promoting a healthier balance of beneficial bacteria. Furthermore, L. reuteri enhances the integrity of the mucosal barrier, which is crucial for preventing the translocation of harmful substances from the gut into the bloodstream. The strain also influences local immune responses by modulating immune receptors like Toll-like receptors (TLRs) in the gut mucosa, leading to anti-inflammatory effects. As a probiotic, it colonizes the gut rather than being absorbed systemically, exerting its effects locally and influencing gut-brain axis signaling related to pain and motility.
Side effects
Limosilactobacillus reuteri strains, including R0830, are generally considered safe for both infants and adults, with a strong safety record. Common side effects, occurring in over 5% of users, are typically mild gastrointestinal symptoms such as transient gas or bloating, especially when supplementation is initiated. Uncommon side effects, affecting 1-5% of individuals, may include rare instances of temporary diarrhea or constipation. Very rare side effects, occurring in less than 1% of cases, include isolated reports of bacteremia in severely immunocompromised patients; however, these are not specific to the R0830 strain and are extremely uncommon in healthy individuals. No significant drug interactions have been reported. The primary contraindication is severe immunocompromise, where caution is advised due to the theoretical risk of systemic infection. L. reuteri is widely used in infants and children with no major safety concerns.
Dosage
For Limosilactobacillus reuteri R0830, specific dosing guidelines are not as well-established as for other L. reuteri strains. However, based on related strains, the minimum effective dose typically ranges from 1 × 10^8 to 1 × 10^9 Colony Forming Units (CFU) daily. The optimal dosage commonly used in clinical trials for other L. reuteri strains is around 10^8–10^9 CFU per day. There is no established maximum safe dose, with studies safely using doses up to 10^10 CFU daily. For optimal survival through gastric acid, it is often recommended to administer L. reuteri with meals. The supplement is available in various forms, including capsules, powders, or liquid formulations. Survival through stomach acid is critical for efficacy, so enteric-coated or freeze-dried forms may enhance viability. No specific cofactors are required for its action.
FAQs
Is Limosilactobacillus reuteri R0830 safe for infants?
While direct data on R0830 is limited, L. reuteri strains are generally safe for infants, especially for colic treatment, and are widely used in this population with a strong safety record.
How long before effects are seen?
Effects on gastrointestinal symptoms typically appear within 1–4 weeks of consistent supplementation, though individual responses may vary.
Can it be taken with antibiotics?
Yes, probiotics can be taken alongside antibiotics to help mitigate antibiotic-associated gut disturbances, but they should be spaced a few hours apart to maximize probiotic viability.
Does it permanently colonize the gut?
Colonization by L. reuteri strains is usually transient, meaning continuous intake is required to maintain the beneficial effects.
Is it effective for IBS?
Some L. reuteri strains have shown effectiveness in improving IBS symptoms. While direct evidence for R0830 is limited, its efficacy is promising based on research of related strains.
Research Sources
- https://pubmed.ncbi.nlm.nih.gov/37742098/ – This systematic review and meta-analysis focused on L. reuteri DSM 17938 in preterm infants. It found that supplementation significantly reduced the incidence of necrotizing enterocolitis and feeding intolerance, confirming its safety and efficacy in this vulnerable population.
- https://pubmed.ncbi.nlm.nih.gov/37147591/ – This systematic review and meta-analysis investigated L. reuteri DSM 17938 in children with gastrointestinal disorders. It concluded that L. reuteri DSM 17938 supplementation significantly reduced diarrhea duration and improved overall gut symptoms, demonstrating its therapeutic potential.
- https://www.frontiersin.org/journals/gastroenterology/articles/10.3389/fgstr.2023.1296048/full – This RCT and meta-analysis on adults with IBS examined L. reuteri DSM 17938 and ATCC PTA 6475. It reported significant improvements in abdominal pain, bloating, and stool consistency compared to placebo, supporting the use of these strains for IBS symptom management.
- https://www.cureus.com/articles/351766-efficacy-of-limosilactobacillus-reuteri-ublru-87-in-infantile-colic-and-its-symptoms-a-double-blind-placebo-controlled-study – This double-blind, placebo-controlled RCT evaluated L. reuteri UBLRu-87, a strain related to R0830, for infantile colic. It found that the strain significantly reduced colic symptoms and improved parental quality of life, indicating its potential benefit in this condition.
